Skip to: Content
Skip to: Site Navigation
Skip to: Search

October 6, 2008 11:36:22 PM CDT



Pill Delivers Prostate Cancer Breakthrough

Posted Jul 22, 08 2:07 AM CDT in Business Science & Health 

(Newser) – A new experimental pill taken once a day is proving effective against an advanced, aggressive form of prostate cancer which has resisted other therapies, reports Reuters. The drug, abiraterone, created by Cougar Biotechnology, significantly shrank tumors in a clinical trial, according to a study in the Journal of Clinical Oncology. It could be available by 2011. Prostate cancer is the second-leading cancer killer of men after lung cancer.

"This drug prevents the cancer from making its own hormones that allow the cancer cells to survive," said the lead researcher. "We believe this drug will make a difference."

Source Reuters

0 comments | Print E-mail | Digg Seed this on Newsvine Add this link to Del.icio.us StumbleUpon
An MRI Image shows suspected prostate cancer, later conformed by biopsy. A new drug has proved effective in shrinking advanced prostate cancer tumors.   (AP Photo)
Skip Ciccarelli, a high school instructor and prostate cancer survivor is on a 1,700 mile kayak trek to promote prostate cancer screening.   (AP Photo)
A new drug used to treat advanced prostate cancer is proving effective.   (AP Photo)
« Prev« Prev | Next »Next » Slideshow
Our editors also recommend:

Threads (
1
 of 1)




Today's Most Popular

Loading...

Other Science & Health Stories


What is Newser?

2008 Codie Finalist

Newser gives you more news in less time. We search for the best and most important stories all over the web, read them for you, and deliver concise and sharp summaries—along with links to the full text. Newser provides a way to stay on top of an ever-expanding horizon of news and opinion—politics, sports, business, trends, technology, personalities, crimes, and controversies. Newser keeps you not just better informed, but, with our signature graphic interface and smart condensed format, more enjoyably informed.

Learn more »